- Home
- / Impel Pharmaceuticals
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Impel Pharmaceuticals financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$0
2024-02-16
Market Capitalization
$5.8 M
2024-02-15
Revenue
$12.7 M
FY, 2022
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2021 | FY, 2022 |
|---|---|---|
| Revenue | 668.0K | 12.7M |
| Cost of goods sold | 691.0K | 6.5M |
| Gross profit | 6.2M | |
| Gross profit margin, % | 48.7% | |
| General and administrative expense | 50.9M | 77.9M |
| Operating expense total | 71.5M | 89.3M |
| EBIT | (71.5M) | (83.2M) |
| EBIT margin, % | -657.5% | |
| Interest expense | 13.8M | |
| Pre tax profit | (76.5M) | (106.3M) |
| Income tax expense | 2.0K | |
| Net Income | (76.5M) | (106.3M) |
| EPS | (4.5) |